Navigating Health and Human Services (HHS’s) Enforcement Discretion Policy Regarding Peptides – What it Means and Reasons to be Wary
On October 28, 2026, HHS announced the availability of “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances,” covering HHS’s enforcement policy regarding the use of certain peptide bulk drug substances in compounding pursuant to section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act). Usually, substances not yet on